iSpecimen (NASDAQ:ISPC) Second Quarter 2024 Results

Key Financial Results

• Revenue: US$2.86m (up 76% from 2Q 2023).

• Net loss: US$2.11m (loss narrowed by 40% from 2Q 2023).

• US$0.19 loss per share (improved from US$0.39 loss in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

iSpecimen EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 32%.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US.

Performance of the American Healthcare Services industry.

The company's shares are down 5.7% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 5 warning signs for iSpecimen (4 shouldn't be ignored) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.